PDCD1 and non-small cell lung carcinoma: Meanwhile, domestic innovative multi‐target agents, such as ivonescimab, a bispecific antibody that targets PD‐1 and VEGF, have demonstrated clinical efficacy comparable to pembrolizumab in advanced NSCLC with positive PD‐L1 expression (PD‐L1 TPS ≥ 1%) in the first‐line setting [58].